Small molecule · Inhibitor of SMARCA2 · developed by ELI LILLY &
LY4050784 is an orally bioavailable allosteric inhibitor of SMARCA2 (BRM), the ATPase subunit of the SWI/SNF (BAF) chromatin remodeling complex. It is being studied in SMARCA4-deficient tumors, including non-small cell lung cancer, where cancer cells depend on SMARCA2 for survival.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06561685 | Phase 1 | Metastatic Solid Tumor | Active not recruiting | LLY |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid TumorMetastatic Solid TumorNon-small Cell Lung CancerSMARCA4-Deficient Tumor
See LLY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LLY catalysts and pipeline →